Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma

被引:13
|
作者
Khaledian, Behnoush [1 ,2 ,3 ]
Taguchi, Ayumu [2 ,3 ]
Shin-ya, Kazuo [4 ]
Kondo-Ida, Lisa [1 ,5 ]
Kagaya, Noritaka [4 ]
Suzuki, Motoshi [1 ,6 ]
Kajino, Taisuke [1 ,2 ,3 ]
Yamaguchi, Tomoya [1 ,7 ]
Shimada, Yukako [1 ,2 ,3 ]
Takahashi, Takashi [1 ,8 ]
机构
[1] Nagoya Univ, Grad Sch Med, Div Mol Carcinogenesis, Ctr Neurol Dis & Canc, Nagoya, Aichi, Japan
[2] Aichi Canc Ctr, Div Mol Diagnost, Nagoya, Aichi, Japan
[3] Nagoya Univ, Grad Sch Med, Dept Canc Diagnost & Therapeut, Div Adv Canc Diagnost, Nagoya, Aichi, Japan
[4] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki, Japan
[5] Nagoya Univ, Grad Sch Med, Dept Occupat & Environm Hlth, Nagoya, Aichi, Japan
[6] Fujita Hlth Univ, Sch Med, Div Mol Oncol, Toyoake, Aichi, Japan
[7] Kumamoto Univ, Prior Org Innovat & Excellence, Kumamoto, Japan
[8] Aichi Canc Ctr, Nagoya, Aichi, Japan
基金
日本学术振兴会;
关键词
geldanamycin; HSP90; lung adenocarcinoma; proteasomal degradation; ROR1; RESISTANCE; HSP90; SURVIVAL; CANCER; ONCOGENE; HEAT-SHOCK-PROTEIN-90; GELDANAMYCIN; NKX2-1/TTF-1; EXPRESSION; CHAPERONE;
D O I
10.1111/cas.14786
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have previously identified receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a direct transcriptional target of TTF-1/NKX2-1, a lineage-survival oncogene in lung adenocarcinoma. ROR1 sustains prosurvival signaling from multiple receptor tyrosine kinases including epidermal growth factor receptor, MET, and insulin-like growth factor 1 receptor in part by maintaining the caveolae structure as a scaffold protein of cavin-1 and caveolin-1. In this study, a high throughput screening of the natural product library containing 2560 compounds was undertaken using a cell-based FluoPPI assay detecting ROR1-cavin-1 interaction. As a result, geldanamycin (GA), a known inhibitor of heat shock protein 90 (HSP90), was identified as a potential inhibitor of ROR1. Geldanamycin, as well as two GA derivatives tested in the clinic, 17-allylamino-17-demethoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), decreased ROR1 protein expression. We found that ROR1 physically interacted with HSP90 alpha, but not with other HSP90 paralogs, HSP90 beta or GRP94. Geldanamycin in turn destabilized and degraded ROR1 protein in a dose- and time-dependent manner through the ubiquitin/proteasome pathway, resulting in a significant suppression of cell proliferation in lung adenocarcinoma cell lines, for which the kinase domain of ROR1, but not its kinase activity or N-glycosylation, was required. Our findings indicate that HSP90 is required to sustain expression of ROR1 crucial for lung adenosarcoma survival, suggesting that inhibition of HSP90 could be a promising therapeutic strategy in ROR1-positive lung adenocarcinoma.
引用
收藏
页码:1225 / 1234
页数:10
相关论文
共 50 条
  • [41] Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains
    Reddy, UR
    Phatak, S
    Pleasure, D
    ONCOGENE, 1996, 13 (07) : 1555 - 1559
  • [42] Characterization of Peripheral B Cells Expressing CLL-Associated Receptor Tyrosine Kinase ROR1 in Healthy Donors
    Milleck, Julia
    Kreuzer, Karl-Anton
    Assenmacher, Mario
    Schmitz, Juergen
    Jaehn, Peter S.
    BLOOD, 2012, 120 (21)
  • [43] Neurite extension in central neurons: a novel role for the receptor tyrosine kinases Ror1 and Ror2
    Paganoni, S
    Ferreira, A
    JOURNAL OF CELL SCIENCE, 2005, 118 (02) : 433 - 446
  • [44] Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies
    Yang, Jiahui
    Baskar, Sivasubramanian
    Kwong, Ka Yin
    Kennedy, Michael G.
    Wiestner, Adrian
    Rader, Christoph
    PLOS ONE, 2011, 6 (06):
  • [45] Targeting Human B Cell Chronic Lymphocytic Leukemia With a Monoclonal Antibody Specific for the Receptor Tyrosine Kinase ROR1
    Baskar, Sivasubramanian
    Yang, Jiahui
    Rader, Christoph
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 969 - 969
  • [46] Functional and clinical significance of ROR1 in lung adenocarcinoma (vol 20, 1085, 2020)
    Schiavone, Giovanna
    Epistolio, Samantha
    Martin, Vittoria
    Molinari, Francesca
    Barizzi, Jessica
    Mazzucchelli, Luca
    Frattini, Milo
    Wannesson, Luciano
    BMC CANCER, 2020, 20 (01)
  • [47] RETRACTED: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells (Retracted article. See vol. 17, 2022)
    Hojjat-Farsangi, Mohammad
    Ghaemimanesh, Fatemeh
    Daneshmanesh, Amir Hossein
    Bayat, Ali-Ahmad
    Mahmoudian, Jafar
    Jeddi-Tehrani, Mahmood
    Rabbani, Hodjatallah
    Mellstedt, Hakan
    PLOS ONE, 2013, 8 (04):
  • [48] Heat shock protein 90 inhibition in the endothelium
    Barabutis, Nektarios
    FRONTIERS IN MEDICINE, 2023, 10
  • [49] Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease
    Potratz, Jenny
    Tillmanns, Amelie
    Berning, Philipp
    Korsching, Eberhard
    Schaefer, Christiane
    Lechtape, Birgit
    Schleithoff, Carolin
    Unland, Rebekka
    Schaefer, Karl-Ludwig
    Mueller-Tidow, Carsten
    Juergens, Heribert
    Dirksen, Uta
    MOLECULAR ONCOLOGY, 2016, 10 (05) : 677 - 692
  • [50] Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
    DaneshManesh, Amir H.
    Mikaelsson, Eva
    Jeddi-Tehrani, Mahmood
    Bayat, Ali Ahmad
    Ghods, Roya
    Ostadkarampour, Mahyar
    Akhondi, Mehdi
    Lagercrantz, Svetlana
    Larsson, Catharina
    Osterborg, Anders
    Shokri, Fazel
    Mellstedt, Hakan
    Rabbani, Hodjattallah
    INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (05) : 1190 - 1195